NCT05210595 is a Phase 4 clinical trial of Clopidogrel 75 mg in Acute Myocardial Infarction, sponsored by Dong-A University.

Who is sponsoring NCT05210595?

NCT05210595 is sponsored by Dong-A University.

What drugs are being tested in NCT05210595?

Interventions in NCT05210595: Clopidogrel 75 mg, Ticagrelor 60mg, Ticagrelor 45 mg.

What condition does NCT05210595 study?

NCT05210595 studies Acute Myocardial Infarction, Ticagrelor.

Is NCT05210595 still recruiting?

NCT05210595 is currently status unknown. Last updated 27 January 2022.

Last reviewed 2022-01-27 · How we verify

NCT05210595

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Optimal Dosage of Ticagrelor in Korean Patients With AMI

Status unknown Phase 4 Last updated 27 January 2022

What this trial tests

Phase 4 trial testing Clopidogrel 75 mg in Acute Myocardial Infarction in 120 participants. Status unknown.

Timeline

1 January 2022

Primary endpoint
31 December 2022

31 December 2023

Quick facts

Lead sponsor	Dong-A University
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	120
Start date	1 January 2022
Primary completion	31 December 2022
Estimated completion	31 December 2023
Sites	1 location across South Korea

Drugs / interventions tested

Clopidogrel 75 mg
Ticagrelor 60mg — full drug profile →
Ticagrelor 45 mg — full drug profile →

Conditions studied

Acute Myocardial Infarction — all drugs for Acute Myocardial Infarction →
Ticagrelor — all drugs for Ticagrelor →

Sponsor

Dong-A University

Who can join

Adults 20 to 75, any sex, with Acute Myocardial Infarction or Ticagrelor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

East Asian patients will be required optimal dose of newer P2Y12 inhibitor (ticagrelor) to determine the safer treatment and better outcome. Whether low dose of ticagrelorI is more adequate for clinical practice in Korea is unclear. Therefore, the investigators aim to evaluate efficacy and safety of low dose of ticagrelor in Acute Myocardial Infarction (AMI) undergoing percutaneous coronary intervention(PCI).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Antiplatelet Therapy Aims and Strategies in Asian Patients with Acute Coronary Syndrome or Stable Coronary Artery Disease.
Tam CC, Tse HF. · · 2022 · cited 6× · PMID 36556067 · DOI 10.3390/jcm11247440

Verify or expand the search:

Other trials of Clopidogrel 75 mg

Trials testing the same drug.

NCT04738097 — Efficacy of Ticagrelor Plus Aspirin in Mild Non-cardioembolic Ischemic Stroke · Phase 3 · completed
NCT03814642 — Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Male Participants · Phase 1 · completed

Other recruiting trials for Acute Myocardial Infarction

Currently open trials in the same condition.

NCT03951467 — Using an Intervention Adapted to the Health Literacy Level to Improve Adherence to Medical Recommendations · NA · recruiting
NCT07536802 — Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention: A Randomized Control Trial · Phase 4 · recruiting
NCT06947135 — Stellate Ganglion Morphine Infiltration on Myocardial Ischemia-Reperfusion Injury · NA · recruiting
NCT06515730 — Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction · Phase 4 · recruiting
NCT07522164 — Acute Myocardial Infarction Clinical Cohort · active not recruiting

Other Dong-A University trials

Trials by the same sponsor.

NCT04755387 — Ticagrelor De-escalation Strategy in AMI Patients · Phase 4 · recruiting
NCT05225077 — Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients · Phase 4 · unknown
NCT04174456 — Combination of Olmesartan Effect on Myocardial Viability of Patients With Dilated Cardiomyopathy · NA · unknown
NCT03570671 — Noninvasive Cardiac Imaging in Vasospastic Angina Korean Registry (NAVIGATOR) · NA · unknown
NCT03731988 — Efficacy of Ablative Fractional Laser-assisted Photodynamic Therapy According to the Laser Density for Actinic Keratosis · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05210595 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dong-A University
Last refreshed: 27 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05210595.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing